This review discusses the currently available literature regarding three controversial indications for sentinel node mapping for breast cancer patients. For women with ductal carcinoma in situ (DCIS), the use of sentinel lymph node mapping (SLNM) should be limited to women having a mastectomy. For patients with multifocal breast carcinoma, SLNM is accurate when a retroareolar injection technique is employed in the procedure. When treatment plans for node-negative patients call for neoadjuvant chemotherapy, accurate sentinel node mapping can be performed prior to the administration of chemotherapy. The resolution of these and other controversies should result in the expansion of the number of patients evaluated with SLNM in the future.
Get full access to this article
View all access options for this article.
References
1.
GiulianoAE.Mapping a pathway for axillary staging: A personal perspective on the current status of sentinel node dissection for breast cancer.Arch Surg1999;134:195–9.
2.
LagiosMD, WestdahlPR, MargolinFR, RoseMR.Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures.Cancer1982;50: 1309–14.
3.
FisherER, SassR, FisherB, . Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS).Cancer1986;57:197–208.
4.
LagiosMD, MargolinFR, WestdahlPR, RoseMR.Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence.Cancer1989;63:618–24.
5.
SilversteinMJ, GiersonED, WaismanJR, . Axillary lymph node dissection for T1a breast carcinoma. Is it indicated?Cancer1994;73:664–7.
6.
FeldmanSM, KragDN, McNallyRK, . Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy.J Am Coll Surg1999;188:248–54.
7.
FuhrmanGM, CederbomGJ, BoltonJS, . Image-guided core-needle breast biopsy is an accurate technique to evaluate patients with nonpalpable imaging abnormalities.Ann Surg1998; 227:932–9.
8.
JackmanRJ, BurbankF, ParkerSH, . Stereotactic breast biopsy of nonpalpable lesions: Determinants of ductal carcinoma in situ underestimation rates.Radiology2001;218:497–502.
9.
PendasS, DauwayE, GiulianoR, . Sentinel node biopsy in ductal carcinoma in situ patients.Ann Surg Oncol2000;7: 15–20.
10.
CoxCE, NguyenK, GrayRJ, . Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): Why map DCIS?Am Surg2001;67:513–21.
11.
Klauber-DeMoreN, TanLK, LibermanL, . Sentinel lymph node biopsy: Is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?Ann Surg Oncol2000;7:636–42.
12.
KellyTA, KimJA, PatrickR, . Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ.Am J Surg2003;186:368–70.
13.
IntraM, VeronesiP, MazzarolC, . Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast.Arch Surg2003;138:309–13.
14.
FarkasEA, StolierAJ, TengSC, . An argument against routine sentinel node mapping for DCIS.Am Surg2004;70:13–8.
15.
SchrenkP, WayandW.Sentinel-node biopsy in axillary lymph-node staging for patients with multicentric breast cancer (letter).Lancet2001;357:122.
16.
TousimisE, Van ZeeKJ, FeyJV. The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancers.J Am Coll Surg2003;197:529–35.
17.
LayeequeR, Henry-TillmanR, KorourianS. Subareolar sentinel node biopsy for multiple breast cancers.Am J Surg2003;186:730–6.
18.
D'Eredia'G, FerrareseF, CecereV, . Subareolar injection may be more accurate that other techniques for sentinel lymph node biopsy in breast cancer.Ann Surg Oncol2003; 10:942–7.
19.
KernKA.Concordance and validation study of sentinel lymph node biopsy for breast cancer using subareolar injection of blue dye and technetium 99m sulfur colloid.J Am Coll Surg2002;195:467–75.
BalchGC, MithaniSK, RichardsKR, . Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and HI breast cancer.Ann Surg Oncol2003;10:616–21.
22.
BradyEW.Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer.Breast J2002;8:97–100.
23.
SchwartzGF, MeltzerAJ.Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast.Breast J2003;9:374–9.
24.
JulianTB, DusiD, WolmarkN.Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer.Am J Surg2002;184:315–7.
25.
ReitsamerR, PeintingerF, RettenbacherL, . Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.J Surg Oncol2003;84:63–7.
26.
BreslinTM, CohenL, SahinA, . Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.J Clin Oncol2000;18:3480–6.
HalsteadWS.The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894. Johns Hopkins Hosp Bull1894–1895; 4:297.
